[1] World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016–2021. Geneva: World Health Organization; 2021. https://apo.who.int/publications/i/item/progress-report-on-hiv-viral-hepatitis-and-sexually-transmitted-infections-2019. [2019-7-1].
[2] Li J, Pang L, Liu ZF. Interpretation of the national action plan for eliminating Hepatitis C as a public health threat (2021-2030). China CDC Wkly, 2022; 4, 627−30.
[3] WHO. Global health sector strategy on viral hepatitis 2016-2021, 2016.https://fctc.who.int/publications/i/item/global-health-sector-strategy-on-viral-hepatitis-2016-2021. [2016-05-17].
[4] National Health Commission of the People’s Republic of China. Notice on the action plan for eliminating public health hazards of hepatitis C (2021-2030), 2021. (In Chinese)
[5] Tanaka J, Yoshizawa H. A national project for the management of viral hepatitis toward prevention of hepatocellular carcinoma in Japan. Gan To Kagaku Ryoho, 2004; 31, 864−70.
[6] Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep, 2012; 61, 1−32.
[7] Orkin C, Leach E, Flanagan S, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? Epidemiol Infect, 2015; 143, 2837−40. doi:  10.1017/S0950268815000199
[8] Bert F, Rindermann A, Abdelfattah MA, et al. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. Eur J Gastroenterol Hepatol, 2016; 28, 1246−52. doi:  10.1097/MEG.0000000000000702
[9] Pandiselvam S, Jena NN, Ghatak-Roy A, et al. Prevalence of undiagnosed HIV, hepatitis B, and hepatitis C among patients in an Indian emergency department. J Am Coll Emerg Physicians Open, 2020; 2, e12328.
[10] Lyons MS, Kunnathur VA, Rouster SD, et al. Prevalence of diagnosed and undiagnosed Hepatitis C in a midwestern urban emergency department. Clin Infect Dis, 2016; 62, 1066−71. doi:  10.1093/cid/ciw073
[11] Liu LL, Xu HQ, Hu Y, et al. Hepatitis C screening in hospitals: find the missing patients. Virol J, 2019; 16, 47. doi:  10.1186/s12985-019-1157-1
[12] Park JS, Wong J, Cohen H. Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications. PLoS One, 2021; 16, e0252976. doi:  10.1371/journal.pone.0252976
[13] Wu G, Zhou AQ, Kwon S. Integrating hepatitis C virus screening of baby boomers at a community hospital emergency department. J Viral Hepat, 2022; 29, 263−70. doi:  10.1111/jvh.13654
[14] Ding GW, Ye SD, Hei FX, et al. Sentinel surveillance for viral hepatitis C in China, 2016-2017. Chin J Endemiol, 2019; 40, 41−45. (In Chinese
[15] Chen YS, Li L, Cui FQ, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol, 2011; 32, 881−91. (In Chinese
[16] AbdulQawi K, Youssef A, Metwally MA, et al. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. Croat Med J, 2010; 51, 219−28. doi:  10.3325/cmj.2010.51.219
[17] National Health Commission of the People’s Republic of China. China's viral hepatitis prevention and control plan (2017-2020), 2017. http://www.nhc.gov.cn/jkj/s3581/201711/aea94a8c1d9d4110a13e2b4d8418c173.shtml. [2017-11-10]. (In Chinese)
[18] Prasad M, Saade GR, Sandoval G, et al. Hepatitis C virus antibody screening in a cohort of pregnant women: identifying seroprevalence and risk factors. Obstet Gynecol, 2020; 135, 778−88. doi:  10.1097/AOG.0000000000003754
[19] Gao YH, Yang J, Sun F, et al. Prevalence of Anti-HCV antibody among the general population in Mainland China between 1991 and 2015: a systematic review and meta-analysis. Open Forum Infect Dis, 2019; 6, ofz040. doi:  10.1093/ofid/ofz040
[20] Zhang B, Wang R, Jiang K, et al. Prevalence of positivity to antibodies to hepatitis C virus among volunteer blood donors in China: a meta-analysis. Public Health, 2021; 199, 87−95. doi:  10.1016/j.puhe.2021.07.011
[21] Maaroufi A, Vince A, Himatt SM, et al. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat, 2017; 24, 8−24. doi:  10.1111/jvh.12762
[22] Rao ZH, Sun LQ, Wang X, et al. HCV RNA test results among anti-HCV positive patients in Bao’an district of Shenzhen, 2016-2019. Chin J AIDS STD, 2020; 26, 625−28. (In Chinese
[23] Al-Mahmood A, Al-Jubori A. The prevalence of Hepatitis C virus among blood donors attending Samarra's general hospital. Infect Disord Drug Targets, 2020; 20, 693−97. doi:  10.2174/1871526519666190916101509
[24] Gheorghe L, Iacob S, Csiki IE, et al. The prevalence of HCV infection and risk factors in a hospital- based population screening, a first step to the micro-elimination of HCV infection in medical institutions from Romania-results of the HepC alert study. J Gastrointestin Liver Dis, 2020; 29, 587−93. doi:  10.15403/jgld-3084
[25] Huang P, Zhu LG, Zhai XJ, et al. Hepatitis C virus infection and risk factors in the general population: a large community-based study in eastern China, 2011-2012. Epidemiol Infect, 2015; 143; 2827−36.
[26] Sun HQ, Xiao GX, Guo Y, et al. Spatial clustering and changing trend of hepatitis C prevalence during 2008-2012 in China. Chin J Public Health, 2014; 3, 286−9. (In Chinese
[27] Li YR, Zhao LR, Geng N, et al. Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data. Virol J, 2020; 17, 36. doi:  10.1186/s12985-020-01316-y
[28] Chlibek R, Smetana J, Sosovickova R, et al. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One, 2017; 12, e0175525. doi:  10.1371/journal.pone.0175525
[29] Zhang MY, Wu RH, Xu HQ, et al. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open, 2019; 9, e028248. doi:  10.1136/bmjopen-2018-028248
[30] Wen J. Study on the current situation of diagnosis and treatment of hepatitis C patients in medical institutions. Chinese Center for Disease Control and Prevention. 2018. (In Chinese)
[31] Li JF, Liu S, Ren F, et al. Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. Int J Infect Dis, 2014; 27, 49−53. doi:  10.1016/j.ijid.2014.07.003
[32] Rao HY, Sun DG, Yang RF, et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol, 2012; 27, 526−32. doi:  10.1111/j.1440-1746.2011.06880.x
[33] Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int, 2011; 31, 30−60. doi:  10.1111/j.1478-3231.2011.02539.x
[34] Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health, 2017; 5, e1192−207. doi:  10.1016/S2214-109X(17)30375-3